Diabetes Clinical Trial
— ADEPTOfficial title:
Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
Verified date | January 2023 |
Source | Tulane University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.
Status | Completed |
Enrollment | 150 |
Est. completion date | June 21, 2021 |
Est. primary completion date | June 21, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years to 70 Years |
Eligibility | Inclusion Criteria: - Men or women ages 40 to 70 years - HbA1c 6.0-6.9% - Willing and able to provide informed consent Exclusion Criteria: - Diagnosed type 1 diabetes mellitus - Use of agents affecting glycemic control (medications for diabetes, oral glucocorticoids) within the past three months prior to enrollment - Medical condition in which low-carbohydrate diet may not be advised: estimated glomerular filtration rate (eGFR) =45 mL/min/1.73 m²; self-report of liver disease due to hepatitis or alcohol; osteoporosis; untreated thyroid disease; gout; cancer (other than non-melanoma skin cancer) requiring treatment in the past year, unless prognosis is excellent - Factors that may affect HbA1c: hemoglobin <11 mg/dL (cutpoint for moderate-to-severe anemia, which could lead to falsely elevated or lowered HbA1c); recent blood donation or blood transfusion (self-report, past 4 months); human immunodeficiency virus (self-report) - Self-reported history of intensive care unit stay due to Coronavirus Disease 2019 (COVID-19) in the past three months, as severe COVID-19 may affect blood glucose levels - Allergies to nuts - For women, current pregnancy, breastfeeding, or plans to become pregnant during the study - Consumption of =21 alcoholic drinks per week or consumption of =6 drinks per occasion - Current or planned residence making it difficult to meet trial requirements (due to distance from study site and/or challenges regularly traveling to site) - Current participation in another lifestyle intervention trial or a pharmaceutical trial - Participation of another household member in the study; employees or persons living with employees of the study - Other concerns regarding ability to meet trial requirements, at the discretion of the principal investigator or study coordinator |
Country | Name | City | State |
---|---|---|---|
United States | Tulane Office of Health Research | New Orleans | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Tulane University School of Public Health and Tropical Medicine | National Institute of General Medical Sciences (NIGMS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in Insulin | 6-month change in fasting insulin comparing low-carbohydrate arm with usual diet arm | Baseline and six months | |
Other | Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) | 6-month change in HOMA-IR comparing low-carbohydrate arm with usual diet arm. HOMA-IR was calculated as fasting insulin (µIU/mL) x fasting glucose (mmol/L)/22.5. | Baseline and six months | |
Other | Change in Diastolic Blood Pressure | 6-month change in diastolic blood pressure comparing low-carbohydrate arm with usual diet arm | Baseline and six months | |
Other | Change in Waist Circumference | 6-month change in waist circumference comparing low-carbohydrate arm with usual diet arm | Baseline and six months | |
Other | Change in Estimated Atherosclerotic Cardiovascular Disease Risk | 6-month change in estimated 10-year atherosclerotic cardiovascular disease risk comparing low-carbohydrate arm with usual diet arm.
The estimated 10-year cardiovascular disease risk was assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score, known as the Pooled Cohort Equations. The Pooled Cohort Equations estimate the 10-year primary risk of ASCVD (atherosclerotic cardiovascular disease) among patients without pre-existing cardiovascular disease who are between 40 and 79 years of age. Variables included in the risk score include: gender, age, race, total cholesterol, HDL cholesterol, systolic blood pressure, treatment for blood pressure, diabetes, and smoking status. Reference: Goff DC, Lloyd-Jones DM et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American college of cardiology/American heart association task force on practice guidelines. Vol. 129, Circulation. 2014. |
Baseline and six months | |
Primary | Change in Hemoglobin A1c | 6-month change in Hemoglobin A1c comparing low-carbohydrate arm with usual diet arm | Baseline and six months | |
Secondary | Change in Fasting Plasma Glucose | 6-month change in fasting plasma glucose comparing low-carbohydrate arm with usual diet arm | Baseline and six months | |
Secondary | Change in Systolic Blood Pressure | 6-month change in systolic blood pressure comparing low-carbohydrate arm with usual diet arm | Baseline and six months | |
Secondary | Change in Total-to-HDL-cholesterol Ratio | 6-month change in total-to-HDL-cholesterol ratio comparing low-carbohydrate arm with usual diet arm | Baseline and six months | |
Secondary | Change in Body Weight | 6-month change in body weight comparing low-carbohydrate arm with usual diet arm | Baseline and six months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |